Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study)

Sun A. Yoon; Byoung G. Han; Sung G. Kim; Sang Y. Han; Young I. Jo; Kyung H. Jeong; Kook H. Oh; Hyeong C. Park; Sun H. Park; Shin W. Kang; Ki R. Na; Sun W. Kang; Nam H. Kim; Young H. Jang; Seong H. Shin; Dae R. Cha

doi:10.1111/dom.12863

Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study)

Sun A. Yoon, Byoung G. Han, Sung G. Kim, Sang Y. Han, Young I. Jo, Kyung H. Jeong, Kook H. Oh, Hyeong C. Park, Sun H. Park, Shin W. Kang, Ki R. Na, Sun W. Kang, Nam H. Kim, Young H. Jang, Seong H. Shin, Dae R. Cha

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Aims: This multicentre, randomized, double-blind study investigated the efficacy and safety of gemigliptin in Korean type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment (RI). Methods: The study comprised a 12-week main part and a 40-week extension. We report here the results from the main part. In total, 132 patients were randomized to receive gemigliptin (n = 66) or placebo (n = 66). Changes in glycated haemoglobin (HbA1c; primary endpoint), other glycaemic control parameters (fasting plasma glucose, glycated albumin and fructosamine), lipid profiles, renal function parameters and safety profiles were evaluated. Results: Baseline characteristics were comparable between the groups (mean HbA1c, 8.4% [68 mmol/mol]; age, 62.0 years; duration of type 2 diabetes, 16.3 years; estimated glomerular filtration rate, 33.3 mL/min/1.73 m²). At Week 12, the adjusted mean change ± standard error in HbA1c with gemigliptin was −0.82% ± 0.14% (−8.9 ± 1.5 mmol/mol), whereas it was 0.38% ± 0.14% (4.2 ± 1.5 mmol/mol) with placebo (significant between-group difference, P <.001). Other glycaemic control parameters showed beneficial changes as well. Body weight change (gemigliptin, −0.3 kg; placebo, −0.2 kg) was not significant. In the gemigliptin group, the mean decrease in urinary albumin creatinine ratio (UACR) was significant, both in patients with microalbuminuria (−41.9 mg/g creatinine, P =.03) and macroalbuminuria (−528.9 mg/g creatinine, P <.001). Drug-related adverse events were similar with gemigliptin and placebo (15% and 12%, respectively). Conclusions: A 12-week treatment with gemigliptin improved glycaemic control and provided UACR reduction in T2DM patients with moderate to severe RI. Gemigliptin was well tolerated, with no additional risk of hypoglycaemia and change in body weight.

Original language	English
Pages (from-to)	590-598
Number of pages	9
Journal	Diabetes, Obesity and Metabolism
Volume	19
Issue number	4
DOIs	https://doi.org/10.1111/dom.12863
Publication status	Published - 2017 Apr 1

Bibliographical note

Funding Information:
The authors thank the CRO (C&R Research Inc., Seoul, Republic of Korea) and staff for the conduct of the study, the patients for their participation, the industry sponsor (LG Life Sciences, Seoul, Republic of Korea) for coordination and funding of the study and Hye-Ryon Kim (Medical Writing, Inc.) for writing assistance. Y. H. J. and S. H. S. are LG Life Sciences employees. None of the other authors reported potential conflicts of interest relevant to this study. All authors participated in the design of the study. All authors except Y. H. J. and S. H. S. conducted the study and contributed toward acquisition of data. S. A. Y. wrote the manuscript. D. R. C. supervised the project and edited the manuscript. Y. H. J. and S. H. S. analysed the data. All authors reviewed and approved the final manuscript.

Publisher Copyright:
© 2016 John Wiley & Sons Ltd

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1111/dom.12863

Fingerprint Dive into the research topics of 'Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study)'. Together they form a unique fingerprint.

Cite this

Yoon, S. A., Han, B. G., Kim, S. G., Han, S. Y., Jo, Y. I., Jeong, K. H., Oh, K. H., Park, H. C., Park, S. H., Kang, S. W., Na, K. R., Kang, S. W., Kim, N. H., Jang, Y. H., Shin, S. H., & Cha, D. R. (2017). Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study). Diabetes, Obesity and Metabolism, 19(4), 590-598. https://doi.org/10.1111/dom.12863

Yoon, Sun A. ; Han, Byoung G. ; Kim, Sung G. ; Han, Sang Y. ; Jo, Young I. ; Jeong, Kyung H. ; Oh, Kook H. ; Park, Hyeong C. ; Park, Sun H. ; Kang, Shin W. ; Na, Ki R. ; Kang, Sun W. ; Kim, Nam H. ; Jang, Young H. ; Shin, Seong H. ; Cha, Dae R. / Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment : A 12-week, double-blind randomized study (the GUARD Study). In: Diabetes, Obesity and Metabolism. 2017 ; Vol. 19, No. 4. pp. 590-598.

@article{d238ff668e374c4b9c6bb34e6742c4bb,

title = "Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study)",

abstract = "Aims: This multicentre, randomized, double-blind study investigated the efficacy and safety of gemigliptin in Korean type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment (RI). Methods: The study comprised a 12-week main part and a 40-week extension. We report here the results from the main part. In total, 132 patients were randomized to receive gemigliptin (n = 66) or placebo (n = 66). Changes in glycated haemoglobin (HbA1c; primary endpoint), other glycaemic control parameters (fasting plasma glucose, glycated albumin and fructosamine), lipid profiles, renal function parameters and safety profiles were evaluated. Results: Baseline characteristics were comparable between the groups (mean HbA1c, 8.4% [68 mmol/mol]; age, 62.0 years; duration of type 2 diabetes, 16.3 years; estimated glomerular filtration rate, 33.3 mL/min/1.73 m2). At Week 12, the adjusted mean change ± standard error in HbA1c with gemigliptin was −0.82% ± 0.14% (−8.9 ± 1.5 mmol/mol), whereas it was 0.38% ± 0.14% (4.2 ± 1.5 mmol/mol) with placebo (significant between-group difference, P <.001). Other glycaemic control parameters showed beneficial changes as well. Body weight change (gemigliptin, −0.3 kg; placebo, −0.2 kg) was not significant. In the gemigliptin group, the mean decrease in urinary albumin creatinine ratio (UACR) was significant, both in patients with microalbuminuria (−41.9 mg/g creatinine, P =.03) and macroalbuminuria (−528.9 mg/g creatinine, P <.001). Drug-related adverse events were similar with gemigliptin and placebo (15% and 12%, respectively). Conclusions: A 12-week treatment with gemigliptin improved glycaemic control and provided UACR reduction in T2DM patients with moderate to severe RI. Gemigliptin was well tolerated, with no additional risk of hypoglycaemia and change in body weight.",

author = "Yoon, {Sun A.} and Han, {Byoung G.} and Kim, {Sung G.} and Han, {Sang Y.} and Jo, {Young I.} and Jeong, {Kyung H.} and Oh, {Kook H.} and Park, {Hyeong C.} and Park, {Sun H.} and Kang, {Shin W.} and Na, {Ki R.} and Kang, {Sun W.} and Kim, {Nam H.} and Jang, {Young H.} and Shin, {Seong H.} and Cha, {Dae R.}",

note = "Funding Information: The authors thank the CRO (C&R Research Inc., Seoul, Republic of Korea) and staff for the conduct of the study, the patients for their participation, the industry sponsor (LG Life Sciences, Seoul, Republic of Korea) for coordination and funding of the study and Hye-Ryon Kim (Medical Writing, Inc.) for writing assistance. Y. H. J. and S. H. S. are LG Life Sciences employees. None of the other authors reported potential conflicts of interest relevant to this study. All authors participated in the design of the study. All authors except Y. H. J. and S. H. S. conducted the study and contributed toward acquisition of data. S. A. Y. wrote the manuscript. D. R. C. supervised the project and edited the manuscript. Y. H. J. and S. H. S. analysed the data. All authors reviewed and approved the final manuscript. Publisher Copyright: {\textcopyright} 2016 John Wiley & Sons Ltd",

year = "2017",

month = apr,

day = "1",

doi = "10.1111/dom.12863",

language = "English",

volume = "19",

pages = "590--598",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "4",

}

Yoon, SA, Han, BG, Kim, SG, Han, SY, Jo, YI, Jeong, KH, Oh, KH, Park, HC, Park, SH, Kang, SW, Na, KR, Kang, SW, Kim, NH, Jang, YH, Shin, SH & Cha, DR 2017, 'Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study)', Diabetes, Obesity and Metabolism, vol. 19, no. 4, pp. 590-598. https://doi.org/10.1111/dom.12863

Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment : A 12-week, double-blind randomized study (the GUARD Study). / Yoon, Sun A.; Han, Byoung G.; Kim, Sung G.; Han, Sang Y.; Jo, Young I.; Jeong, Kyung H.; Oh, Kook H.; Park, Hyeong C.; Park, Sun H.; Kang, Shin W.; Na, Ki R.; Kang, Sun W.; Kim, Nam H.; Jang, Young H.; Shin, Seong H.; Cha, Dae R.

In: Diabetes, Obesity and Metabolism, Vol. 19, No. 4, 01.04.2017, p. 590-598.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment

T2 - A 12-week, double-blind randomized study (the GUARD Study)

AU - Yoon, Sun A.

AU - Han, Byoung G.

AU - Kim, Sung G.

AU - Han, Sang Y.

AU - Jo, Young I.

AU - Jeong, Kyung H.

AU - Oh, Kook H.

AU - Park, Hyeong C.

AU - Park, Sun H.

AU - Kang, Shin W.

AU - Na, Ki R.

AU - Kang, Sun W.

AU - Kim, Nam H.

AU - Jang, Young H.

AU - Shin, Seong H.

AU - Cha, Dae R.

N1 - Funding Information: The authors thank the CRO (C&R Research Inc., Seoul, Republic of Korea) and staff for the conduct of the study, the patients for their participation, the industry sponsor (LG Life Sciences, Seoul, Republic of Korea) for coordination and funding of the study and Hye-Ryon Kim (Medical Writing, Inc.) for writing assistance. Y. H. J. and S. H. S. are LG Life Sciences employees. None of the other authors reported potential conflicts of interest relevant to this study. All authors participated in the design of the study. All authors except Y. H. J. and S. H. S. conducted the study and contributed toward acquisition of data. S. A. Y. wrote the manuscript. D. R. C. supervised the project and edited the manuscript. Y. H. J. and S. H. S. analysed the data. All authors reviewed and approved the final manuscript. Publisher Copyright: © 2016 John Wiley & Sons Ltd

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Aims: This multicentre, randomized, double-blind study investigated the efficacy and safety of gemigliptin in Korean type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment (RI). Methods: The study comprised a 12-week main part and a 40-week extension. We report here the results from the main part. In total, 132 patients were randomized to receive gemigliptin (n = 66) or placebo (n = 66). Changes in glycated haemoglobin (HbA1c; primary endpoint), other glycaemic control parameters (fasting plasma glucose, glycated albumin and fructosamine), lipid profiles, renal function parameters and safety profiles were evaluated. Results: Baseline characteristics were comparable between the groups (mean HbA1c, 8.4% [68 mmol/mol]; age, 62.0 years; duration of type 2 diabetes, 16.3 years; estimated glomerular filtration rate, 33.3 mL/min/1.73 m2). At Week 12, the adjusted mean change ± standard error in HbA1c with gemigliptin was −0.82% ± 0.14% (−8.9 ± 1.5 mmol/mol), whereas it was 0.38% ± 0.14% (4.2 ± 1.5 mmol/mol) with placebo (significant between-group difference, P <.001). Other glycaemic control parameters showed beneficial changes as well. Body weight change (gemigliptin, −0.3 kg; placebo, −0.2 kg) was not significant. In the gemigliptin group, the mean decrease in urinary albumin creatinine ratio (UACR) was significant, both in patients with microalbuminuria (−41.9 mg/g creatinine, P =.03) and macroalbuminuria (−528.9 mg/g creatinine, P <.001). Drug-related adverse events were similar with gemigliptin and placebo (15% and 12%, respectively). Conclusions: A 12-week treatment with gemigliptin improved glycaemic control and provided UACR reduction in T2DM patients with moderate to severe RI. Gemigliptin was well tolerated, with no additional risk of hypoglycaemia and change in body weight.

AB - Aims: This multicentre, randomized, double-blind study investigated the efficacy and safety of gemigliptin in Korean type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment (RI). Methods: The study comprised a 12-week main part and a 40-week extension. We report here the results from the main part. In total, 132 patients were randomized to receive gemigliptin (n = 66) or placebo (n = 66). Changes in glycated haemoglobin (HbA1c; primary endpoint), other glycaemic control parameters (fasting plasma glucose, glycated albumin and fructosamine), lipid profiles, renal function parameters and safety profiles were evaluated. Results: Baseline characteristics were comparable between the groups (mean HbA1c, 8.4% [68 mmol/mol]; age, 62.0 years; duration of type 2 diabetes, 16.3 years; estimated glomerular filtration rate, 33.3 mL/min/1.73 m2). At Week 12, the adjusted mean change ± standard error in HbA1c with gemigliptin was −0.82% ± 0.14% (−8.9 ± 1.5 mmol/mol), whereas it was 0.38% ± 0.14% (4.2 ± 1.5 mmol/mol) with placebo (significant between-group difference, P <.001). Other glycaemic control parameters showed beneficial changes as well. Body weight change (gemigliptin, −0.3 kg; placebo, −0.2 kg) was not significant. In the gemigliptin group, the mean decrease in urinary albumin creatinine ratio (UACR) was significant, both in patients with microalbuminuria (−41.9 mg/g creatinine, P =.03) and macroalbuminuria (−528.9 mg/g creatinine, P <.001). Drug-related adverse events were similar with gemigliptin and placebo (15% and 12%, respectively). Conclusions: A 12-week treatment with gemigliptin improved glycaemic control and provided UACR reduction in T2DM patients with moderate to severe RI. Gemigliptin was well tolerated, with no additional risk of hypoglycaemia and change in body weight.

UR - http://www.scopus.com/inward/record.url?scp=85013467019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013467019&partnerID=8YFLogxK

U2 - 10.1111/dom.12863

DO - 10.1111/dom.12863

M3 - Article

C2 - 28019072

AN - SCOPUS:85013467019

VL - 19

SP - 590

EP - 598

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 4

ER -

Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study)

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this